BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $59.00 --0%
Revenue Growth %: +13.2%
Financial Fact:
Provision for income taxes: -24.02M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Revenue Growth %: +13.2%
Financial Fact:
Provision for income taxes: -24.02M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.96, $0.61 better than the analyst estimate of $0.35. Revenue for the quarter came in at $712 million versus the consensus estimate of $662.05 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $3.10-$3.25, versus the consensus of $2.87. BioMarin Pharma sees FY2024 revenue of $2.75-2.82 billion, versus the consensus of $2.74 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ByteDance looks to finalize in-house CPU design, seeks to power its own infrastructure - SCMP
- Helus Pharma reports $148M net loss, closes $50M offering
- Zentek licenses silver technology to sell air filters in the U.S.
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
